Imke Bartelink
Overview
Explore the profile of Imke Bartelink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oudejans E, Witkamp D, Hu-A-Ng G, Hoogterp L, van Rooijen-van Leeuwen G, Kruijff I, et al.
Life Sci Alliance
. 2024 Jan;
7(3).
PMID: 38171595
The leukodystrophy vanishing white matter (VWM) is characterized by chronic and episodic acute neurological deterioration. Curative treatment is presently unavailable. Pathogenic variants in the genes encoding eukaryotic initiation factor 2B...
2.
Cornelissen F, Markert G, Deutsch G, Antonara M, Faaij N, Bartelink I, et al.
J Med Chem
. 2023 May;
66(11):7253-7267.
PMID: 37217193
The blood-brain barrier (BBB) represents a major obstacle to delivering drugs to the central nervous system (CNS), resulting in the lack of effective treatment for many CNS diseases including brain...
3.
Witkamp D, Oudejans E, Hu-A-Ng G, Hoogterp L, Krzywanska A, Znidarsic M, et al.
Ann Clin Transl Neurol
. 2022 Jul;
9(8):1147-1162.
PMID: 35778832
Objective: Vanishing white matter (VWM) is a leukodystrophy, characterized by stress-sensitive neurological deterioration and premature death. It is currently without curative treatment. It is caused by bi-allelic pathogenic variants in...
4.
Karagozoglu K, Helder M, Bot J, Kamp O, Forouzanfar T, Brand H, et al.
BMJ Open
. 2020 Oct;
10(9):e033542.
PMID: 32998913
Introduction: We established a promising sialendoscopic treatment for in vivo enhancement of salivation in salivary glands affected by Sjögren's syndrome (SS). In this technique, the ducts of the salivary glands...
5.
Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, et al.
J Clin Oncol
. 2017 Feb;
35(11):1231-1239.
PMID: 28221861
Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response...
6.
Long-Boyle J, Savic R, Yan S, Bartelink I, Musick L, French D, et al.
Ther Drug Monit
. 2014 Aug;
37(2):236-45.
PMID: 25162216
Background: Population pharmacokinetic (PK) studies of busulfan in children have shown that individualized model-based algorithms provide improved targeted busulfan therapy when compared with conventional dose guidelines. The adoption of population...
7.
Kerl K, Diestelhorst C, Bartelink I, Boelens J, Trame M, Boos J, et al.
Pediatr Blood Cancer
. 2013 Nov;
61(2):306-11.
PMID: 24174393
Background: Busulfan (Bu) is a DNA-alkylating agent used for myeloablative conditioning in stem cell transplantation in children and adults. While the use of intravenous rather than oral administration of Bu...
8.
van Kooij B, Fijnheer R, de Boer J, Dam-van Loon N, Bartelink I, Roest M, et al.
Am J Ophthalmol
. 2006 Mar;
141(4):646-51.
PMID: 16564798
Purpose: To analyze the effect of angiotensin-converting enzyme (ACE) inhibitor lisinopril on inflammatory cystoid macular edema and visual acuity. Design: Randomized, double-blind, placebo-controlled cross-over trial. Methods: setting: Outpatient clinic of...
9.
Thomas H, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, et al.
Br J Clin Pharmacol
. 2002 Feb;
53(1):83-91.
PMID: 11849199
Aims: Cisplatin and carboplatin are often used in combination with etoposide. In a randomized cross-over study, the potential interaction between the two platinum drugs and the metabolism of etoposide was...